The Health and Human Services Department is weighing plans to “drastically” cut the federal government’s funding for domestic HIV prevention, people familiar with the matter told The Wall Street Journal’s Liz Essley Whyte, Dominique Mosbergen and Jonathan Rockoff. Plans could be announced as soon as within a day, though they haven’t been finalized and could be pulled back or adjusted, the report noted. ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Pfizer (PFE) and Shionogi (SGIOY) as shareholders, as well as Gilead Sciences (GILD) are makers of HIV prevention treatments.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Trump Trade: Administration explores simplified plans for reciprocal tariffs
- Big pharma fears drug price spikes in US-EU tariff spat, Reuters says
- GSK Pharma put volume heavy and directionally bearish
- ViiV announces new study data showing zero HIV cases with Apretude
- ViiV Healthcare announces data from EMBRACE Phase IIb study
Questions or Comments about the article? Write to editor@tipranks.com